Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Efficacy and tolerability of asenapine for acute mania in bipolar I disorder: meta-analyses of randomized-controlled trials.

Vita A, De Peri L, Siracusano A, Sacchetti E; ATOM group.

Int Clin Psychopharmacol. 2013 Sep;28(5):219-27. doi: 10.1097/YIC.0b013e32836290d2.

PMID:
23719049
2.

Asenapine: a review of its use in the management of mania in adults with bipolar I disorder.

Chwieduk CM, Scott LJ.

CNS Drugs. 2011 Mar;25(3):251-67. doi: 10.2165/11206700-000000000-00000. Review.

PMID:
21323396
3.

Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes.

Sawyer L, Azorin JM, Chang S, Rinciog C, Guiraud-Diawara A, Marre C, Hansen K.

J Med Econ. 2014 Jul;17(7):508-19. doi: 10.3111/13696998.2014.914030. Epub 2014 Apr 30.

PMID:
24720805
4.

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.

De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU.

CNS Drugs. 2012 Sep 1;26(9):733-59. doi: 10.2165/11634500-000000000-00000. Review.

PMID:
22900950
5.

Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials.

Szegedi A, Zhao J, van Willigenburg A, Nations KR, Mackle M, Panagides J.

BMC Psychiatry. 2011 Jun 20;11:101. doi: 10.1186/1471-244X-11-101.

6.

Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.

Citrome L.

Int J Clin Pract. 2009 Dec;63(12):1762-84. doi: 10.1111/j.1742-1241.2009.02228.x. Epub 2009 Oct 14. Review.

PMID:
19840150
7.

Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.

Szegedi A, Calabrese JR, Stet L, Mackle M, Zhao J, Panagides J; Apollo Study Group.

J Clin Psychopharmacol. 2012 Feb;32(1):46-55. doi: 10.1097/JCP.0b013e31823f872f.

PMID:
22198448
8.

Asenapine: a clinical review of a second-generation antipsychotic.

Stoner SC, Pace HA.

Clin Ther. 2012 May;34(5):1023-40. doi: 10.1016/j.clinthera.2012.03.002. Epub 2012 Apr 10. Review.

PMID:
22494521
9.

Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study.

McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J.

J Affect Disord. 2010 Nov;126(3):358-65. doi: 10.1016/j.jad.2010.04.005.

PMID:
20537396
10.

Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses.

Azorin JM, Sapin C, Weiller E.

J Affect Disord. 2013 Feb 15;145(1):62-9. doi: 10.1016/j.jad.2012.07.013. Epub 2012 Aug 4.

PMID:
22868059
11.

Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.

McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J.

J Affect Disord. 2010 Apr;122(1-2):27-38. doi: 10.1016/j.jad.2009.12.028. Epub 2010 Jan 22.

PMID:
20096936
12.

A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states.

McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J.

Bipolar Disord. 2009 Nov;11(7):673-86. doi: 10.1111/j.1399-5618.2009.00748.x. Erratum in: Bipolar Disord. 2010 May;12(3):350.

PMID:
19839993
13.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
14.

Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: a post hoc analysis.

Berk M, Tiller JW, Zhao J, Yatham LN, Malhi GS, Weiller E.

J Clin Psychiatry. 2015 Jun;76(6):728-34. doi: 10.4088/JCP.13m08827.

15.

Asenapine: Efficacy and safety of 5 and 10mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder.

Landbloom RL, Mackle M, Wu X, Kelly L, Snow-Adami L, McIntyre RS, Mathews M, Hundt C.

J Affect Disord. 2016 Jan 15;190:103-110. doi: 10.1016/j.jad.2015.06.059. Epub 2015 Sep 25.

PMID:
26496015
16.

Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: a meta-analysis of placebo-controlled trials.

Muralidharan K, Ali M, Silveira LE, Bond DJ, Fountoulakis KN, Lam RW, Yatham LN.

J Affect Disord. 2013 Sep 5;150(2):408-14. doi: 10.1016/j.jad.2013.04.032. Epub 2013 Jun 2.

PMID:
23735211
17.

Asenapine: a review of acute and extension phase data in bipolar disorder.

McIntyre RS.

CNS Neurosci Ther. 2011 Dec;17(6):645-8. doi: 10.1111/j.1755-5949.2010.00200.x. Epub 2010 Oct 15. Review.

PMID:
20950326
18.

Asenapine treatment and health-related quality of life in patients experiencing bipolar I disorder with mixed episodes: post-hoc analyses of pivotal trials.

Michalak EE, Guiraud-Diawara A, Sapin C.

Curr Med Res Opin. 2014 Apr;30(4):711-8. doi: 10.1185/03007995.2013.874988. Epub 2014 Jan 10.

PMID:
24329543
19.

Asenapine versus olanzapine in acute mania: a double-blind extension study.

McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J.

Bipolar Disord. 2009 Dec;11(8):815-26. doi: 10.1111/j.1399-5618.2009.00749.x. Epub 2009 Oct 14. Erratum in: Bipolar Disord. 2010 Feb;12(1):112.

PMID:
19832806
20.

Use of asenapine as add-on therapy in the treatment of bipolar disorder: a comprehensive review and case series.

Dell'Osso B, Cremaschi L, Palazzo MC, Spagnolin G, Cattaneo A, Grancini B, Maggi M, Altamura AC.

Expert Opin Drug Saf. 2014 Sep;13(9):1199-208. doi: 10.1517/14740338.2014.938047. Epub 2014 Aug 1. Review.

PMID:
25084462

Supplemental Content

Support Center